Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Apple COO Jeff Williams discusses Apple Watch Series 4. Photo: Noah Berger/AFP/Getty Images
Health care economist Aaron Carroll is here to rain on the parade surrounding the new Apple Watch and its heart-monitoring features.
The details: Writing in the New York Times, Carroll says the risk of false positives — the watch telling people they have a heart irregularity that isn’t really there — is too high.
- Experts have previously recommended against widespread heart monitoring, Carroll notes.
- And the Apple Watch will primarily appeal to a low-risk population to begin with.
“This is one of the major problems with such a device. The people most in need of it, those who might benefit from tests and distance monitoring, are the least likely to get it. If we truly believed this was a medical test beneficial to the general population, insurance should pay for it. No one is suggesting that should happen,” he writes in NYT.